Lyra Therapeutics Ownership 2024 | Who Owns Lyra Therapeutics Now?
Institutional Ownership
51.08%
Insider Ownership
0.66%
Retail Ownership
48.27%
Institutional Holders
51.00
Lyra Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 19.93% | 0.08% | 12,757,562 | - | - | 3,533,844 | Jun 30, 2024 |
| BLACKROCK INC. | 4.42% | - | 2,829,978 | 2,678,059 | 1762.82% | 783,055 | Jun 30, 2024 |
| SAMSARA BIOCAPITAL, LLC | 4.34% | 0.16% | 2,780,261 | - | - | 769,298 | Jun 30, 2024 |
| VANGUARD GROUP INC | 2.70% | - | 1,730,915 | 249,434 | 16.84% | 478,944 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 1.65% | 0.05% | 1,056,829 | - | - | 292,424 | Jun 30, 2024 |
| ROSALIND ADVISORS, INC. | 1.62% | 0.22% | 1,034,773 | -109,751 | -9.59% | 286,321 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 1.54% | 0.00% | 985,631 | 985,631 | 100.00% | 271,000 | Jun 30, 2024 |
| MORGAN STANLEY | 1.27% | - | 811,745 | 747,353 | 1160.63% | 224,610 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.18% | - | 755,095 | 395,664 | 110.08% | 208,966 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.77% | 0.00% | 490,861 | 307,118 | 167.15% | 135,821 | Jun 30, 2024 |
| NEW YORK STATE COMMON RETIREMENT FUND | 0.60% | 0.00% | 382,900 | 382,900 | 100.00% | 106,000 | Jun 30, 2024 |
| STATE STREET CORP | 0.41% | - | 259,820 | 133,640 | 105.91% | 71,892,000 | Jun 30, 2024 |
| CAPTION MANAGEMENT, LLC | 0.39% | 0.00% | 246,600 | 246,600 | 100.00% | 68,234 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.36% | 0.00% | 232,670 | - | - | 64,380 | Jun 30, 2024 |
| SIMPLEX TRADING, LLC | 0.20% | - | 129,141 | 129,141 | 100.00% | 35,000 | Jun 30, 2024 |
| CLEARLINE CAPITAL LP | 0.19% | 0.00% | 119,128 | - | - | 32,963 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.17% | - | 111,609 | 111,609 | 100.00% | 30,882 | Jun 30, 2024 |
| BANK OF AMERICA CORP /DE/ | 0.14% | - | 86,459 | -73,138 | -45.83% | 23,863 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.13% | - | 83,860 | 23,365 | 38.62% | 23,204,000 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.12% | - | 77,423 | 77,423 | 100.00% | 21,423 | Jun 30, 2024 |
Lyra Therapeutics's largest institutional shareholder is PERCEPTIVE ADVISORS LLC, holding 19.93% of the company's total share outstanding, currently valued at $3.53M. The top 10 institutional shareholders own together 39.42% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ROSALIND ADVISORS, INC. | 1.62% | 0.22% | 1,034,773 | -109,751 | -9.59% | 286,321 | Jun 30, 2024 |
| SAMSARA BIOCAPITAL, LLC | 4.34% | 0.16% | 2,780,261 | - | - | 769,298 | Jun 30, 2024 |
| PERCEPTIVE ADVISORS LLC | 19.93% | 0.08% | 12,757,562 | - | - | 3,533,844 | Jun 30, 2024 |
| IKARIAN CAPITAL, LLC | 1.65% | 0.05% | 1,056,829 | - | - | 292,424 | Jun 30, 2024 |
| ALPINE GLOBAL MANAGEMENT, LLC | 0.07% | 0.00% | 46,439 | 46,439 | 100.00% | 12,850 | Jun 30, 2024 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.36% | 0.00% | 232,670 | - | - | 64,380 | Jun 30, 2024 |
| DLK INVESTMENT MANAGEMENT, LLC | 0.02% | 0.00% | 12,000 | - | - | 3,320 | Jun 30, 2024 |
| CAPTION MANAGEMENT, LLC | 0.39% | 0.00% | 246,600 | 246,600 | 100.00% | 68,234 | Jun 30, 2024 |
| CLEARLINE CAPITAL LP | 0.19% | 0.00% | 119,128 | - | - | 32,963 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 1.54% | 0.00% | 985,631 | 985,631 | 100.00% | 271,000 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.05% | 0.00% | 33,951 | 33,951 | 100.00% | 9,394 | Jun 30, 2024 |
| VIRTU FINANCIAL LLC | 0.05% | 0.00% | 31,690 | 19,762 | 165.68% | 9,000 | Jun 30, 2024 |
| Y-INTERCEPT (HONG KONG) LTD | 0.04% | 0.00% | 27,516 | 6,985 | 34.02% | 7,614 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.77% | 0.00% | 490,861 | 307,118 | 167.15% | 135,821 | Jun 30, 2024 |
| LETKO, BROSSEAU & ASSOCIATES INC | 0.05% | 0.00% | 31,900 | - | - | 8,827 | Jun 30, 2024 |
| NEW YORK STATE COMMON RETIREMENT FUND | 0.60% | 0.00% | 382,900 | 382,900 | 100.00% | 106,000 | Jun 30, 2024 |
| AMERITAS INVESTMENT PARTNERS, INC. | 0.01% | - | 4,741 | 4,741 | 100.00% | 1,312 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.04% | - | 26,036 | 26,036 | 100.00% | 7,465 | Jun 30, 2024 |
| TOWER RESEARCH CAPITAL LLC (TRC) | 0.01% | - | 6,822 | -2,099 | -23.53% | 1,890 | Jun 30, 2024 |
| SIMPLEX TRADING, LLC | 0.20% | - | 129,141 | 129,141 | 100.00% | 35,000 | Jun 30, 2024 |
The largest Lyra Therapeutics shareholder by % of total assets is ROSALIND ADVISORS, INC.. The company owns 1.03M shares of Lyra Therapeutics (LYRA), representing 0.22% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BLACKROCK INC. | 4.42% | - | 2,829,978 | 2,678,059 | 1762.82% | 783,055 | Jun 30, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 1.54% | 0.00% | 985,631 | 985,631 | 100.00% | 271,000 | Jun 30, 2024 |
| MORGAN STANLEY | 1.27% | - | 811,745 | 747,353 | 1160.63% | 224,610 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.18% | - | 755,095 | 395,664 | 110.08% | 208,966 | Jun 30, 2024 |
| NEW YORK STATE COMMON RETIREMENT FUND | 0.60% | 0.00% | 382,900 | 382,900 | 100.00% | 106,000 | Jun 30, 2024 |
| TWO SIGMA INVESTMENTS, LP | 0.77% | 0.00% | 490,861 | 307,118 | 167.15% | 135,821 | Jun 30, 2024 |
| VANGUARD GROUP INC | 2.70% | - | 1,730,915 | 249,434 | 16.84% | 478,944 | Jun 30, 2024 |
| CAPTION MANAGEMENT, LLC | 0.39% | 0.00% | 246,600 | 246,600 | 100.00% | 68,234 | Jun 30, 2024 |
| STATE STREET CORP | 0.41% | - | 259,820 | 133,640 | 105.91% | 71,892,000 | Jun 30, 2024 |
| SIMPLEX TRADING, LLC | 0.20% | - | 129,141 | 129,141 | 100.00% | 35,000 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.17% | - | 111,609 | 111,609 | 100.00% | 30,882 | Jun 30, 2024 |
| BANK OF NEW YORK MELLON CORP | 0.12% | - | 77,423 | 77,423 | 100.00% | 21,423 | Jun 30, 2024 |
| ALPINE GLOBAL MANAGEMENT, LLC | 0.07% | 0.00% | 46,439 | 46,439 | 100.00% | 12,850 | Jun 30, 2024 |
| RHUMBLINE ADVISERS | 0.07% | - | 43,385 | 43,089 | 14557.09% | 12,013 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.05% | 0.00% | 33,951 | 33,951 | 100.00% | 9,394 | Jun 30, 2024 |
| ALLIANCEBERNSTEIN L.P. | 0.05% | - | 33,120 | 33,120 | 100.00% | 9,164 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.04% | - | 26,036 | 26,036 | 100.00% | 7,465 | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.13% | - | 83,860 | 23,365 | 38.62% | 23,204,000 | Jun 30, 2024 |
| VIRTU FINANCIAL LLC | 0.05% | 0.00% | 31,690 | 19,762 | 165.68% | 9,000 | Jun 30, 2024 |
| WELLS FARGO & COMPANY/MN | 0.03% | - | 17,618 | 17,367 | 6919.12% | 4,875 | Jun 30, 2024 |
As of Jun 30 2024, Lyra Therapeutics's largest institutional buyer is BLACKROCK INC.. The company purchased 2.68M stocks of LYRA, valued at $783.05K.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| NANTAHALA CAPITAL MANAGEMENT, LLC | - | - | - | -2,820,982 | -100.00% | - | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | - | - | - | -2,742,460 | -100.00% | - | Jun 30, 2024 |
| VR ADVISER, LLC | - | - | - | -2,576,093 | -100.00% | - | Jun 30, 2024 |
| PURA VIDA INVESTMENTS, LLC | - | - | - | -1,413,242 | -100.00% | - | Jun 30, 2024 |
| ALLY BRIDGE GROUP (NY) LLC | - | - | - | -1,003,741 | -100.00% | - | Jun 30, 2024 |
| TRI LOCUM PARTNERS LP | - | - | - | -978,793 | -100.00% | - | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | - | - | - | -800,000 | -100.00% | - | Jun 30, 2024 |
| VERITION FUND MANAGEMENT LLC | - | - | - | -768,214 | -100.00% | - | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | - | - | - | -747,827 | -100.00% | - | Jun 30, 2024 |
| WOODLINE PARTNERS LP | - | - | - | -676,554 | -100.00% | - | Jun 30, 2024 |
| PARKMAN HEALTHCARE PARTNERS LLC | - | - | - | -642,245 | -100.00% | - | Jun 30, 2024 |
| ENSIGN PEAK ADVISORS, INC | - | - | - | -591,311 | -100.00% | - | Jun 30, 2024 |
| INVESCO LTD. | 0.04% | - | 22,824 | -532,409 | -95.89% | 6,315 | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | - | - | - | -528,118 | -100.00% | - | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 0.03% | - | 20,350 | -385,771 | -94.99% | 5,631 | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | - | - | - | -357,319 | -100.00% | - | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.04% | - | 24,391 | -310,274 | -92.71% | 6,749 | Jun 30, 2024 |
| HUDSON BAY CAPITAL MANAGEMENT LP | - | - | - | -250,000 | -100.00% | - | Jun 30, 2024 |
| ALYESKA INVESTMENT GROUP, L.P. | - | - | - | -240,723 | -100.00% | - | Jun 30, 2024 |
| ACUTA CAPITAL PARTNERS, LLC | - | - | - | -173,320 | -100.00% | - | Jun 30, 2024 |
As of Jun 30 2024, Lyra Therapeutics's biggest institutional seller is NANTAHALA CAPITAL MANAGEMENT, LLC. The company sold -2.82M shares of LYRA, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ACADIAN ASSET MANAGEMENT LLC | 1.54% | 0.00% | 985,631 | 985,631 | 100.00% | 271,000 | Jun 30, 2024 |
| NEW YORK STATE COMMON RETIREMENT FUND | 0.60% | 0.00% | 382,900 | 382,900 | 100.00% | 106,000 | Jun 30, 2024 |
| CAPTION MANAGEMENT, LLC | 0.39% | 0.00% | 246,600 | 246,600 | 100.00% | 68,234 | Jun 30, 2024 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.17% | - | 111,609 | 111,609 | 100.00% | 30,882 | Jun 30, 2024 |
| ALPINE GLOBAL MANAGEMENT, LLC | 0.07% | 0.00% | 46,439 | 46,439 | 100.00% | 12,850 | Jun 30, 2024 |
| XTX TOPCO LTD | 0.05% | 0.00% | 33,951 | 33,951 | 100.00% | 9,394 | Jun 30, 2024 |
| ALLIANCEBERNSTEIN L.P. | 0.05% | - | 33,120 | 33,120 | 100.00% | 9,164 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.04% | - | 26,036 | 26,036 | 100.00% | 7,465 | Jun 30, 2024 |
| AMERITAS INVESTMENT PARTNERS, INC. | 0.01% | - | 4,741 | 4,741 | 100.00% | 1,312 | Jun 30, 2024 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 0.01% | - | 3,507 | 3,507 | 100.00% | 970 | Jun 30, 2024 |
| FARTHER FINANCE ADVISORS, LLC | 0.00% | - | 38 | 38 | 100.00% | 11 | Jun 30, 2024 |
Lyra Therapeutics's largest new institutional shareholder by number of shares is ACADIAN ASSET MANAGEMENT LLC, purchased 985.63K shares, valued at $271.00K, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| NANTAHALA CAPITAL MANAGEMENT, LLC | - | - | - | -2,820,982 | -100.00% | - | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | - | - | - | -2,742,460 | -100.00% | - | Jun 30, 2024 |
| VR ADVISER, LLC | - | - | - | -2,576,093 | -100.00% | - | Jun 30, 2024 |
| PURA VIDA INVESTMENTS, LLC | - | - | - | -1,413,242 | -100.00% | - | Jun 30, 2024 |
| ALLY BRIDGE GROUP (NY) LLC | - | - | - | -1,003,741 | -100.00% | - | Jun 30, 2024 |
| TRI LOCUM PARTNERS LP | - | - | - | -978,793 | -100.00% | - | Jun 30, 2024 |
| VESTAL POINT CAPITAL, LP | - | - | - | -800,000 | -100.00% | - | Jun 30, 2024 |
| VERITION FUND MANAGEMENT LLC | - | - | - | -768,214 | -100.00% | - | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | - | - | - | -747,827 | -100.00% | - | Jun 30, 2024 |
| WOODLINE PARTNERS LP | - | - | - | -676,554 | -100.00% | - | Jun 30, 2024 |
| PARKMAN HEALTHCARE PARTNERS LLC | - | - | - | -642,245 | -100.00% | - | Jun 30, 2024 |
| ENSIGN PEAK ADVISORS, INC | - | - | - | -591,311 | -100.00% | - | Jun 30, 2024 |
| WALLEYE CAPITAL LLC | - | - | - | -528,118 | -100.00% | - | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | - | - | - | -357,319 | -100.00% | - | Jun 30, 2024 |
| HUDSON BAY CAPITAL MANAGEMENT LP | - | - | - | -250,000 | -100.00% | - | Jun 30, 2024 |
| ALYESKA INVESTMENT GROUP, L.P. | - | - | - | -240,723 | -100.00% | - | Jun 30, 2024 |
| ACUTA CAPITAL PARTNERS, LLC | - | - | - | -173,320 | -100.00% | - | Jun 30, 2024 |
| SUPERSTRING CAPITAL MANAGEMENT LP | - | - | - | -145,284 | -100.00% | - | Jun 30, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -131,902 | -100.00% | - | Jun 30, 2024 |
| HRT FINANCIAL LP | - | - | - | -98,525 | -100.00% | - | Jun 30, 2024 |
| MAN GROUP PLC | - | - | - | -90,283 | -100.00% | - | Jun 30, 2024 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | - | - | - | -86,800 | -100.00% | - | Jun 30, 2024 |
| MARATHON TRADING INVESTMENT MANAGEMENT LLC | - | - | - | -67,010 | -100.00% | - | Jun 30, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | - | - | - | -50,900 | -100.00% | - | Jun 30, 2024 |
| CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. | - | - | - | -41,563 | -100.00% | - | Jun 30, 2024 |
| EXODUSPOINT CAPITAL MANAGEMENT, LP | - | - | - | -32,118 | -100.00% | - | Jun 30, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | - | - | - | -31,459 | -100.00% | - | Jun 30, 2024 |
| AMERICAN CENTURY COMPANIES INC | - | - | - | -25,778 | -100.00% | - | Jun 30, 2024 |
| OCCUDO QUANTITATIVE STRATEGIES LP | - | - | - | -22,820 | -100.00% | - | Jun 30, 2024 |
| OMERS ADMINISTRATION CORP | - | - | - | -22,200 | -100.00% | - | Jun 30, 2024 |
| CUBIST SYSTEMATIC STRATEGIES, LLC | - | - | - | -21,160 | -100.00% | - | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | - | - | - | -20,187 | -100.00% | - | Jun 30, 2024 |
| PRELUDE CAPITAL MANAGEMENT, LLC | - | - | - | -15,400 | -100.00% | - | Jun 30, 2024 |
| BREVAN HOWARD CAPITAL MANAGEMENT LP | - | - | - | -14,042 | -100.00% | - | Jun 30, 2024 |
| BANK OF MONTREAL /CAN/ | - | - | - | -13,900 | -100.00% | - | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | - | - | - | -11,670 | -100.00% | - | Jun 30, 2024 |
| JEFFERIES FINANCIAL GROUP INC. | - | - | - | -11,400 | -100.00% | - | Jun 30, 2024 |
| ENGINEERS GATE MANAGER LP | - | - | - | -10,718 | -100.00% | - | Jun 30, 2024 |
| HERITAGE WEALTH MANAGEMENT, INC./TEXAS | - | - | - | -10,000 | -100.00% | - | Jun 30, 2024 |
| POINT72 ASIA (SINGAPORE) PTE. LTD. | - | - | - | -5,710 | -100.00% | - | Jun 30, 2024 |
| MACQUARIE GROUP LTD | - | - | - | -1,375 | -100.00% | - | Jun 30, 2024 |
Lyra Therapeutics's largest sold out institutional shareholder by shares sold is NANTAHALA CAPITAL MANAGEMENT, LLC, sold -2.82M shares, valued at -, as of undefined.
Lyra Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| MERIDIAN FUND INC | 0.16% | 386,663 | - | - | Mar 28, 2024 |
| BRIDGEWAY FUNDS INC | 0.04% | 84,900 | -55,000 | -39.31% | Mar 28, 2024 |
| Bernstein Fund Inc | 0.01% | 58,310 | - | - | Mar 31, 2024 |
| VANGUARD INDEX FUNDS | 0.00% | 1,420,776 | 7,637 | 0.54% | Mar 31, 2024 |
| FEDERATED HERMES INSURANCE SERIES | 0.00% | 12,000 | - | - | Mar 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.00% | 10,669 | - | - | Mar 31, 2024 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 318,083 | 35,947 | 12.74% | Feb 29, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.00% | 769 | - | - | Mar 31, 2024 |
| VICTORY PORTFOLIOS | 0.00% | 29,550 | - | - | Mar 31, 2024 |
| FIRST TRUST EXCHANGE-TRADED FUND | 0.00% | 9,242 | - | - | Mar 31, 2024 |
| Federated Hermes Equity Funds | 0.00% | 18,000 | - | - | Jan 31, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 21,838 | -1,526 | -6.53% | Mar 31, 2024 |
| SEASONS SERIES TRUST | 0.00% | 13,550 | - | - | Mar 31, 2024 |
| SCHWAB CAPITAL TRUST | 0.00% | 9,060 | - | - | Jan 31, 2024 |
| Calvert Variable Products, Inc. | 0.00% | 363 | - | - | Mar 31, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 7,641 | 7,481 | 4675.63% | Feb 29, 2024 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 69,022 | 40,882 | 145.28% | Jan 31, 2024 |
| SunAmerica Specialty Series | 0.00% | 34 | - | - | Apr 30, 2021 |
| Dimensional ETF Trust | 0.00% | 28,416 | 17,425 | 158.54% | Jan 31, 2024 |
| RUSSELL INVESTMENT CO | 0.00% | 13,688 | - | - | Jan 31, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 5,276 | 4,330 | 457.72% | Jan 31, 2024 |
| PGIM ETF TRUST | 0.00% | 2,368 | - | - | Feb 29, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 5,400 | 1,318 | 32.29% | Jan 31, 2024 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 1,200 | - | - | Mar 31, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 17,913 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 2,339 | - | - | Mar 28, 2024 |
| Blackstone Alternative Investment Funds | 0.00% | 2,000 | 1,700 | 566.67% | Mar 31, 2024 |
| FIDELITY SALEM STREET TRUST | 0.00% | 53,955 | - | - | Mar 31, 2024 |
| ProFunds | 0.00% | 147 | - | - | Mar 31, 2024 |
| VALIC Co I | 0.00% | 3,229 | - | - | Feb 29, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 20,803 | - | - | Feb 29, 2024 |
| AIM INVESTMENT FUNDS (INVESCO INVESTMENT FUNDS) | 0.00% | 142,757 | - | - | Jan 31, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 1,258 | - | - | Mar 31, 2024 |
| AIM VARIABLE INSURANCE FUNDS (INVESCO VARIABLE INSURANCE FUNDS) | 0.00% | 20,300 | - | - | Mar 31, 2024 |
| PACE SELECT ADVISORS TRUST | 0.00% | 2,639 | - | - | Jan 31, 2024 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 119 | - | - | Feb 29, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 394 | - | - | Feb 29, 2024 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 9,765 | - | - | Dec 31, 2023 |
| iSHARES TRUST | 0.00% | 42,979 | 1,960 | 4.78% | Mar 31, 2024 |
| EQ ADVISORS TRUST | 0.00% | 3,034 | -7 | -0.23% | Mar 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 6,745 | - | - | Mar 31, 2024 |
| SUNAMERICA SERIES TRUST | 0.00% | 736 | - | - | Mar 31, 2024 |
| PACIFIC SELECT FUND | 0.00% | 3,716 | - | - | Mar 31, 2024 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 1,968 | 1,968 | - | Mar 31, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 773 | - | - | Dec 31, 2023 |
| Bridge Builder Trust | 0.00% | 2,250 | - | - | Mar 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 785 | 231 | 41.70% | Mar 31, 2024 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 6,234 | - | - | Feb 29, 2024 |
| PRINCIPAL FUNDS, INC. | 0.00% | 1,268 | - | - | Feb 29, 2024 |
| BlackRock Variable Series Funds, Inc. | 0.00% | 594 | - | - | Mar 31, 2024 |
Lyra Therapeutics's largest mutual fund holder by % of total assets is "MERIDIAN FUND INC", owning 386.66K shares, compromising 0.16% of its total assets.
Lyra Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 51 | -37.80% |
| 31 Mar, 24 | 82 | 30.16% |
| 31 Dec, 23 | 63 | 34.04% |
| 30 Sep, 23 | 47 | 14.63% |
| 30 Jun, 23 | 41 | 28.13% |
| 31 Mar, 23 | 32 | -17.95% |
| 31 Dec, 22 | 39 | 8.33% |
| 30 Sep, 22 | 36 | 12.50% |
| 30 Jun, 22 | 32 | 33.33% |
| 31 Mar, 22 | 24 | -25.00% |
| 31 Dec, 21 | 32 | -5.88% |
| 30 Sep, 21 | 34 | -12.82% |
| 30 Jun, 21 | 39 | -20.41% |
| 31 Mar, 21 | 49 | 11.36% |
| 31 Dec, 20 | 44 | 12.82% |
| 30 Sep, 20 | 39 | -9.30% |
| 30 Jun, 20 | 43 | - |
As of 30 Jun 24, 51 institutions are holding Lyra Therapeutics's shares, representing a decrease of -37.80% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 32,695,273 | -28.23% |
| 31 Mar, 24 | 45,556,221 | 7.55% |
| 31 Dec, 23 | 42,358,020 | 32.66% |
| 30 Sep, 23 | 31,928,716 | -5.25% |
| 30 Jun, 23 | 33,698,803 | 78.06% |
| 31 Mar, 23 | 18,925,568 | -0.78% |
| 31 Dec, 22 | 19,074,085 | -0.43% |
| 30 Sep, 22 | 19,156,792 | -0.27% |
| 30 Jun, 22 | 19,207,739 | 282.37% |
| 31 Mar, 22 | 5,023,310 | -2.16% |
| 31 Dec, 21 | 5,134,227 | -22.99% |
| 30 Sep, 21 | 6,667,084 | -4.48% |
| 30 Jun, 21 | 6,980,102 | -7.67% |
| 31 Mar, 21 | 7,560,213 | -12.05% |
| 31 Dec, 20 | 8,596,073 | 12.27% |
| 30 Sep, 20 | 7,656,414 | 8.80% |
| 30 Jun, 20 | 7,037,350 | - |
Lyra Therapeutics (LYRA) has 32.70M shares outstanding as of 30 Jun 24, down -28.23% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 51.08% | 0.61% |
| 31 Mar, 24 | 91.47% | 1.65% |
| 31 Dec, 23 | 74.37% | 1.39% |
| 30 Sep, 23 | 73.10% | 0.87% |
| 30 Jun, 23 | 91.49% | 3.47% |
| 31 Mar, 23 | 51.38% | 1.29% |
| 31 Dec, 22 | 63.08% | 2.33% |
| 30 Sep, 22 | 52.02% | 1.62% |
| 30 Jun, 22 | 56.58% | 25.84% |
| 31 Mar, 22 | 14.80% | 6.47% |
| 31 Dec, 21 | 15.12% | 3.92% |
| 30 Sep, 21 | 19.64% | 4.65% |
| 30 Jun, 21 | 20.56% | 4.15% |
| 31 Mar, 21 | 22.27% | 3.47% |
| 31 Dec, 20 | 25.32% | 4.98% |
| 30 Sep, 20 | 22.55% | 5.25% |
| 30 Jun, 20 | 20.73% | - |
As of 30 Jun 24, Lyra Therapeutics is held by 51.08% institutional shareholders, representing a 0.61% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 28 | -47.17% |
| 31 Mar, 24 | 53 | 17.78% |
| 31 Dec, 23 | 45 | 80.00% |
| 30 Sep, 23 | 25 | 8.70% |
| 30 Jun, 23 | 23 | 187.50% |
| 31 Mar, 23 | 8 | -52.94% |
| 31 Dec, 22 | 17 | 13.33% |
| 30 Sep, 22 | 15 | -28.57% |
| 30 Jun, 22 | 21 | 200.00% |
| 31 Mar, 22 | 7 | -46.15% |
| 31 Dec, 21 | 13 | 30.00% |
| 30 Sep, 21 | 10 | -23.08% |
| 30 Jun, 21 | 13 | -43.48% |
| 31 Mar, 21 | 23 | -30.30% |
| 31 Dec, 20 | 33 | 106.25% |
| 30 Sep, 20 | 16 | -62.79% |
| 30 Jun, 20 | 43 | - |
28 institutional shareholders have increased their position in LYRA stock as of 30 Jun 24 compared to 53 in the previous quarter (a -47.17% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 12 | -14.29% |
| 31 Mar, 24 | 14 | 366.67% |
| 31 Dec, 23 | 3 | -50.00% |
| 30 Sep, 23 | 6 | 20.00% |
| 30 Jun, 23 | 5 | 66.67% |
| 31 Mar, 23 | 3 | -50.00% |
| 31 Dec, 22 | 6 | -33.33% |
| 30 Sep, 22 | 9 | 50.00% |
| 30 Jun, 22 | 6 | -14.29% |
| 31 Mar, 22 | 7 | -30.00% |
| 31 Dec, 21 | 10 | -33.33% |
| 30 Sep, 21 | 15 | -11.76% |
| 30 Jun, 21 | 17 | 21.43% |
| 31 Mar, 21 | 14 | 366.67% |
| 31 Dec, 20 | 3 | -78.57% |
| 30 Sep, 20 | 14 | - |
| 30 Jun, 20 | - | - |
12 institutional shareholders have reduced their position in LYRA stock as of 30 Jun 24 compared to 14 in the previous quarter (a -14.29% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 51 | -37.80% | 32,695,273 | -28.23% | 51.08% | 0.61% | 28 | -47.17% | 12 | -14.29% |
| 31 Mar, 24 | 82 | 30.16% | 45,556,221 | 7.55% | 91.47% | 1.65% | 53 | 17.78% | 14 | 366.67% |
| 31 Dec, 23 | 63 | 34.04% | 42,358,020 | 32.66% | 74.37% | 1.39% | 45 | 80.00% | 3 | -50.00% |
| 30 Sep, 23 | 47 | 14.63% | 31,928,716 | -5.25% | 73.10% | 0.87% | 25 | 8.70% | 6 | 20.00% |
| 30 Jun, 23 | 41 | 28.13% | 33,698,803 | 78.06% | 91.49% | 3.47% | 23 | 187.50% | 5 | 66.67% |
| 31 Mar, 23 | 32 | -17.95% | 18,925,568 | -0.78% | 51.38% | 1.29% | 8 | -52.94% | 3 | -50.00% |
| 31 Dec, 22 | 39 | 8.33% | 19,074,085 | -0.43% | 63.08% | 2.33% | 17 | 13.33% | 6 | -33.33% |
| 30 Sep, 22 | 36 | 12.50% | 19,156,792 | -0.27% | 52.02% | 1.62% | 15 | -28.57% | 9 | 50.00% |
| 30 Jun, 22 | 32 | 33.33% | 19,207,739 | 282.37% | 56.58% | 25.84% | 21 | 200.00% | 6 | -14.29% |
| 31 Mar, 22 | 24 | -25.00% | 5,023,310 | -2.16% | 14.80% | 6.47% | 7 | -46.15% | 7 | -30.00% |
| 31 Dec, 21 | 32 | -5.88% | 5,134,227 | -22.99% | 15.12% | 3.92% | 13 | 30.00% | 10 | -33.33% |
| 30 Sep, 21 | 34 | -12.82% | 6,667,084 | -4.48% | 19.64% | 4.65% | 10 | -23.08% | 15 | -11.76% |
| 30 Jun, 21 | 39 | -20.41% | 6,980,102 | -7.67% | 20.56% | 4.15% | 13 | -43.48% | 17 | 21.43% |
| 31 Mar, 21 | 49 | 11.36% | 7,560,213 | -12.05% | 22.27% | 3.47% | 23 | -30.30% | 14 | 366.67% |
| 31 Dec, 20 | 44 | 12.82% | 8,596,073 | 12.27% | 25.32% | 4.98% | 33 | 106.25% | 3 | -78.57% |
| 30 Sep, 20 | 39 | -9.30% | 7,656,414 | 8.80% | 22.55% | 5.25% | 16 | -62.79% | 14 | - |
| 30 Jun, 20 | 43 | - | 7,037,350 | - | 20.73% | - | 43 | - | - | - |
Lyra Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Insider Sells
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
All Insider Owners Trades
The last insider buy of LYRA was made by Waksal Harlan on Nov 13 2023, buying 25,000 shares at $2.96 per share (worth $74.09K).
Lyra Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 6 | - | - |
| Q1 2024 | 5 | - | - |
| Q4 2023 | 1 | - | - |
| Q2 2023 | 23 | - | - |
| Q1 2023 | 9 | - | - |
| Q3 2022 | 1 | - | - |
| Q2 2022 | 27 | - | - |
| Q1 2022 | 9 | - | - |
| Q3 2021 | 1 | - | - |
| Q2 2021 | 7 | - | - |
| Q1 2021 | 5 | - | - |
| Q4 2020 | 2 | - | - |
| Q3 2020 | 1 | - | - |
| Q2 2020 | 57 | 77 | 74.03% |
| Q1 2020 | - | - | - |
6 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Lyra Therapeutics's insiders, as of Q2 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | - | - | - |
| Q1 2024 | - | - | - |
| Q4 2023 | 1 | - | - |
| Q2 2023 | 14 | - | - |
| Q1 2023 | - | - | - |
| Q3 2022 | - | - | - |
| Q2 2022 | 14 | - | - |
| Q1 2022 | - | - | - |
| Q3 2021 | - | - | - |
| Q2 2021 | 1 | - | - |
| Q1 2021 | - | - | - |
| Q4 2020 | 1 | - | - |
| Q3 2020 | - | - | - |
| Q2 2020 | 12 | 11 | 109.09% |
| Q1 2020 | - | - | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Lyra Therapeutics's stocks.
Lyra Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| NUVB | Nuvation Bio Inc. |
| CGEM | Cullinan Oncology, Inc. |
| ACHL | Achilles Therapeutics plc |
| NXTC | NextCure, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| SPRO | Spero Therapeutics, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| ASMB | Assembly Biosciences, Inc. |
| AUTL | Autolus Therapeutics plc |
| NLTX | Neurogene Inc. |
| TIL | Instil Bio, Inc. |
LYRA Ownership FAQ
Who Owns Lyra Therapeutics?
Lyra Therapeutics is owned by institutional shareholders (51.08%), insiders (0.66%), and public (48.27%). The largest institutional shareholder of Lyra Therapeutics is PERCEPTIVE ADVISORS LLC (19.93% of total shares) and the top mutual fund owner is MERIDIAN FUND INC (0.16% of total shares).
Who are the major institutional shareholders of Lyra Therapeutics?
Lyra Therapeutics's major institutional shareholders are PERCEPTIVE ADVISORS LLC, BLACKROCK INC., SAMSARA BIOCAPITAL, LLC, VANGUARD GROUP INC, and IKARIAN CAPITAL, LLC. The top five shareholders own together 33.05% of the company's share outstanding.
How many Lyra Therapeutics shareholders are there?
As of Jun 2024, there are 51 institutional shareholders of Lyra Therapeutics.
What percentage of Lyra Therapeutics is owned by PERCEPTIVE ADVISORS LLC?
PERCEPTIVE ADVISORS LLC owns 12.76M shares of Lyra Therapeutics, representing 19.93% of the company's total shares outstanding, valued at $3.53M (as of Jun 2024).
What percentage of Lyra Therapeutics is owned by BLACKROCK INC?
As of Jun 2024, BLACKROCK INC holds 2.83M shares of Lyra Therapeutics (LYRA), compromising 4.42% of the company, valued at $783.06K.
What percentage of Lyra Therapeutics is owned by SAMSARA BIOCAPITAL, LLC?
SAMSARA BIOCAPITAL, LLC is the third largest holder of Lyra Therapeutics. The company owns 2.78M of the company's shares outstanding (worth $769.3K).